Monday, 11 Aug 2025
  • About Us
  • Contact Us
  • Terms and Conditions
  • Privacy Policy
Subscribe
Life Care News
  • Home
  • Business
    • Business Wire
    • Globenews Wire
  • News
    NewsShow More
    HR Path Strengthens Global Presence with Strategic Acquisition of PredictiveHR
    11/08/2025
    Manulife to Acquire Comvest Credit Partners, Creating a Leading Private Credit Platform
    Manulife to Acquire Comvest Credit Partners, Creating a Leading Private Credit Platform
    10/08/2025
    Bybit Crypto Insights Report: Everything You Need to Know About Project Crypto
    Bybit Crypto Insights Report: Everything You Need to Know About Project Crypto
    10/08/2025
    MiTAC Computing Partners with Industry Leaders on Open AI Server Solutions at OCP APAC Summit 2025
    MiTAC Computing Partners with Industry Leaders on Open AI Server Solutions at OCP APAC Summit 2025
    09/08/2025
    NOTICE OF SETTLEMENT APPROVAL
    NOTICE OF SETTLEMENT APPROVAL
    09/08/2025
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
  • 🔥
  • news
  • june
  • july
  • global
  • Business
  • today
  • announced
  • Tech
  • company
  • will
Font ResizerAa
Life Care NewsLife Care News
  • Home
  • Business
  • News
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
Search
  • Home
  • Business
    • Business Wire
    • Globenews Wire
  • News
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
Follow US
© 2022 Foxiz News Network. Ruby Design Company. All Rights Reserved.
Health

ITM and ILL Extend Collaboration on the Manufacturing and Supply of Medical Lutetium-177 Radioisotope

GlobeNews Wire
Last updated: 16/06/2025 3:53 PM
GlobeNews Wire
Share
6 Min Read
ITM and ILL Extend Collaboration on the Manufacturing and Supply of Medical Lutetium-177 Radioisotope
SHARE
ITM and ILL Extend Collaboration on the Manufacturing and Supply of Medical Lutetium-177 Radioisotope

Garching / Munich, Germany, and Grenoble, France, June 16, 2025 – ITM Isotope Technologies Munich SE (ITM) and the Institut Laue-Langevin (ILL), today announced an extension of their collaboration for medical radioisotope production, originally established in 2009. Under the terms of the renewed agreement, ITM will receive priority access to half of the available neutron irradiation capacity at ILL’s High-Flux Reactor, its neutron irradiation facility, for the production of non-carrier-added Lutetium-177 (n.c.a. Lu-177), a critical medical radioisotope used for radiopharmaceutical therapies for cancer treatment and diagnosis. As the globally leading manufacturer of n.c.a. Lu-177, ITM is committed to maintaining and expanding its robust manufacturing and production capabilities to meet the growing demand for this vital medical radioisotope.

“ITM and ILL’s longstanding partnership began in 2009, when the radiopharmaceutical industry was still in its infancy,” commented Dr. Andrew Cavey, CEO of ITM. “Our priority access to ILL’s renowned high-flux irradiation services is incredibly important as the demand for n.c.a. Lutetium-177 grows and as our radiopharmaceutical pipeline evolves.”

The high neutron flux of ILL’s reactor provides ITM with a high yield of Lu-177, and allows for a particularly sustainable production of the medical radioisotope by minimizing use of the scarce precursor raw material, Ytterbium-176 (Yb-176). Providing radioisotopes to ITM plays a significant role in enabling geographic and industrial return from ILL to its funding countries, fostering innovation and supporting advancements in radiopharmaceutical research and production.

Dr. Ken Andersen, Director of the Institut Laue-Langevin added, “ILL operates the world-leading neutron source for research by neutron scattering and in nuclear and particle physics. Moreover, ILL’s reactor provides irradiation positions at exceptionally high neutron flux that are exploited both for fundamental research and the production of radionuclides for medical applications. ILL is proud of the longstanding collaboration with ITM, regularly performing irradiations of Ytterbium-176 targets for ITM over the last 15 years, and looks forward to an even closer partnership in the coming years.”


About Radiopharmaceutical Therapy (RPT)
Radiopharmaceutical Therapy (RPT) is an emerging class of cancer therapeutics, which seeks to deliver radiation directly to the tumor while minimizing radiation exposure to healthy tissue. Targeted radiopharmaceuticals are created by linking a therapeutic radioisotope such as Lutetium-177 or Actinium-225 to a targeting molecule (e.g., peptide, antibody, small molecule) that can precisely recognize tumor cells and bind to tumor-specific characteristics, such as receptors on the tumor cell surface. As a result, the radioisotope accumulates at the tumor site and decays, releasing a small amount of ionizing radiation, with the goal of destroying tumor tissue. The precise localization enables targeted treatment with potentially minimal impact to healthy surrounding tissue.

About ITM Isotope Technologies Munich SE
ITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiomolecular precision therapeutics and diagnostics for hard-to-treat tumors. We aim to meet the needs of cancer patients, clinicians and our partners through excellence in development, production and global supply. With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including two phase III studies, combining the company’s high-quality radioisotopes with a range of targeting molecules. By leveraging our nearly two decades of pioneering radiopharma expertise, central industry position and established global network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcome and quality of life. www.itm-radiopharma.com

About the ILL, Institut Laue-Langevin
The ILL is the world-leading facility in neutron science and technology. Delivering the most intense neutron beams in the world to its unparalleled suite of 43 state-of-the-art neutron scattering instruments, the ILL offers a unique tool for probing the heart of matter. Every year, around 1500 international researchers visit the ILL to carry out over 1000 cutting-edge experiments in a variety of disciplines, including physics, chemistry, biology, and material science and engineering. Besides its impact in scientific research and education excellence, the ILL helps drive innovation in the fields of health, energy, the environment and quantum materials. The ILL is engaged in the production of radioisotopes for medical applications since more than 15 years now. A major European project, the ILL was founded in Grenoble in 1967 by France and Germany, joined a few years later by the UK. Today, 13 countries fund the facility for their research communities.

ITM Contact
Corporate Communications
Kathleen Noonan / Julia Westermeir
Phone: +49 89 329 8986 1500
Email:

communications@itm-radiopharma.com

Investor Relations
Ben Orzelek
Phone: +49 89 329 8986 1009
Email:

investors@itm-radiopharma.com

ILL Contact
Radionuclide Production
Ulli Köster 
Phone: (+33) (0)4 76 20 71 54
Email:

koester@ill.fr

Communications
Catarina Espirito Santo
Phone: (+33) (0)4 76 20 71 07
Email:

communication@ill.fr

  • 20250616_ITM and ILL Extend Collaboration on the Manufacturing and Supply of Medical Lutetium-177 Radioisotope
RLJ Lodging Trust Announces Dividends for Second Quarter of 2025
100 Years of DEKRA: Safety in a Changing World
Global AI Spotlight: DataGlobal Hub Assembles Hundreds of Industry Leaders for GDAI 2025, The Largest Global Virtual AI & Data Conference
John Hinshaw Joins Digile as Strategic Advisor & Mentor to Accelerate AI-Led Growth and Global Expansion
Altizon Launches APEX Alliance for Azure channel partners
TAGGED:accessand grenobleannounceddemandextensionfrancegarchinggermanyhighhighfluxillillsinstitutirradiationisotopeitmjunelauelangevinlutetiummedicalmunichncaneutronpriorityproductionradioisotoperadiopharmaceuticalreactortechnologiestoday
Share This Article
Facebook Copy Link Print
- Advertisement -

Your Trusted Source for Accurate and Timely Updates!

Our commitment to accuracy, impartiality, and delivering breaking news as it happens has earned us the trust of a vast audience. Stay ahead with real-time updates on the latest events, trends.
FacebookLike
XFollow
PinterestPin
InstagramFollow
YoutubeSubscribe
LinkedInFollow
MediumFollow

Most Selling Products

Top Picks, Trending Now – Discover the Best Sellers!
Tecno Camon 20 Premier 5G

Tecno Camon 20 Premier 5G

Dark Welkin | 8GB RAM + 512GB Storage (Expandable RAM up to 16GB) | Industry’s 1st 50MP RGBW-Pro Camera | Segment-First 108MP Ultra-Wide Macro Lens | 6.67" 120Hz 10-bit AMOLED In-Display

iQOO Z10 Lite 5G

iQOO Z10 Lite 5G

Titanium Blue | 6GB RAM + 128GB Storage | Dimensity 6300 5G with 433K+ AnTuTu Score | Robust 6000mAh Battery | IP64 Rated + Military-Grade Shock Resistance

OnePlus 13s

OnePlus 13s

Black Velvet | 12GB RAM + 256GB Storage | Flagship Snapdragon® 8 Elite Chipset | Exceptional Battery Life in a Compact Form | Lifetime Display Warranty Included

Samsung Galaxy A55 5G

Samsung Galaxy A55 5G

Awesome Iceblue | 8GB RAM + 256GB Storage | Premium Metal Frame | 50MP OIS Main Camera with Nightography | IP67 Water & Dust Resistance | Gorilla Glass Victus+ | sAMOLED Display with Vision Booster

You Might Also Like

SBI Life crowdsources future-facing AI solutions from India’s Next-Gen Talent pool at the 2025 Hack-AI-Thon finale
Tech

SBI Life crowdsources future-facing AI solutions from India’s Next-Gen Talent pool at the 2025 Hack-AI-Thon finale

20/06/2025

Las Vegas News Briefs April 2025

04/07/2025
Hightouch Named Snowflake Marketers & Advertisers Data Cloud Product Partner of the Year
Business

Hightouch Named Snowflake Marketers & Advertisers Data Cloud Product Partner of the Year

04/06/2025
SunnyMining mobile cloud mining APP is launched: mining real cryptocurrency BTC with zero threshold
Tech

SunnyMining mobile cloud mining APP is launched: mining real cryptocurrency BTC with zero threshold

06/06/2025
Life Care News
Facebook Twitter Youtube Rss Medium

Life Care News:


We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.

Top Categories
  • Home
  • Business
  • News
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
Usefull Links
  • About Us
  • Contact Us
  • Terms and Conditions
  • Privacy Policy
Copyright © 2015 – 2025 LifeCareNews Network. All Rights Reserved. LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Life Care NewsLife Care News
Copyright © 2015 - 2025 LifeCareNews Network. All Rights Reserved. LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?